Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Ahmedabad (NIPER-A), India.
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Ahmedabad (NIPER-A), India.
J Pharm Sci. 2024 Nov;113(11):3246-3254. doi: 10.1016/j.xphs.2024.08.007. Epub 2024 Aug 22.
The selection of quality excipients is a crucial step in peptide formulation development. Apart from excipient incompatibility, process-related impurities or degradants of an excipient can interact with peptide-active pharmaceutical ingredients, forming the interaction products. The formaldehyde has been reported as an impurity of excipient in polyethylene glycol, glycerol, magnesium stearate, microcrystalline cellulose, mannitol, etc. The peptide contains various amino acids such as histidine, lysine, and arginine having free amine groups. These amine groups act as strong nucleophile and can increase the reactivity of peptides. PLGA is the most widely used biodegradable polymer in sustained-release formulations. The hydrolysis of PLGA generates glycolic acid and lactic acid impurities, which can form the interaction product with the amines of peptides. During the formulation development of Liraglutide, we have found few interaction products. The systematic characterization and mechanistic understanding of these interaction products lead us to imidazopyrimidine, glycolyl, and lactolyl moieties. These interaction products have been characterized thoroughly with the use of LC-HRMS, MS/MS, and hydrogen-deuterium exchange mass studies. The study revealed that the reactivity of N-terminal histidine must be considered for formulation development. Moreover, the quality of excipients with respect to presence of impurities must be considered as critical material attributes.
选择高质量的辅料是肽类药物制剂开发的关键步骤。除了辅料不相容性之外,辅料的工艺相关杂质或降解产物可能与肽类活性药物成分相互作用,形成相互作用产物。甲醛已被报道为聚乙二醇、甘油、硬脂酸镁、微晶纤维素、甘露醇等辅料的杂质。肽类含有各种具有游离氨基的氨基酸,如组氨酸、赖氨酸和精氨酸。这些氨基作为强亲核试剂,可以增加肽类的反应活性。PLGA 是缓控释制剂中最广泛使用的可生物降解聚合物。PLGA 的水解会产生乙二醇酸和乳酸杂质,这些杂质可以与肽类的胺基形成相互作用产物。在利拉鲁肽的制剂开发过程中,我们发现了一些相互作用产物。对这些相互作用产物进行系统的表征和机理研究,我们发现了咪唑并嘧啶、乙二酰基和内酯基部分。这些相互作用产物已经通过 LC-HRMS、MS/MS 和氢氘交换质谱研究进行了彻底的表征。该研究表明,在制剂开发过程中必须考虑 N-末端组氨酸的反应性。此外,必须将辅料的质量(杂质的存在)视为关键的物料属性。